DAVID S. GOLDSTEIN, M.D.

Chesapeake Urology Associates, P.A.
Greater Baltimore Medical Center (GBMC)
Physicians Pavilion North
6535 N. Charles Street, Suite 625
Baltimore, MD 21204
410-825-5454 - Office
410-825-5811 - Fax

BOARD CERTIFICATION:

American Board of Urology
– Certified: 1996
– Recertified: 2006

EDUCATION:

1983 Boston University, Boston, MA
Bachelor of Arts in Biology
Graduated Cum Laude

1987 Mount Sinai School of Medicine, New York, NY
Doctor of Medicine.

INTERNSHIP:

1987-1988 Morristown Memorial Hospital, Morristown, NJ
– General Surgery

RESIDENCY TRAINING:

1988-1989 Morristown Memorial Hospital, Morristown, NJ
– General Surgery

1989-1990 UCLA School of Medicine, Los Angeles, CA
– Urology, Junior Resident

1990-1994 Harvard Program in Urology, Boston, MA
Brigham and Women?s Hospital
Chief Resident in Urology 1993-1994

WORK HISTORY:

1999-Present Chesapeake Urology Associates

2001-Present Chesapeake Urology Research Associates

1996-1999 Siegel & Langer, M.D., P A., 6569 N. Charles Street,

1994-1996 Melvin Duckett, M.D., P.A., The Urology Center at Charles North

HOSPITAL AFFILIATIONS:

Greater Baltimore Medical Center

COURSE FACULTY:

Management of Urinary Incontinence Course
Greater Baltimore Medical Center
Baltimore, MD. June 24, 1995.

Pediatric Endourology and Laparoscopy Course
Children's Hospital-Division of Urology
Harvard Medical School
Boston, MA. April 1-4, 1993.

Urological Laparoscopy Course
The Centre for the Study of Endosurgery
Monash Medical School - Alfred Hospital
Melbourne, Australia. August 28-29, 1992.

Laparoscopic Urologic Surgery Course
Brigham and Women's Hospital
Harvard Medical School
Boston, MA. April 3-5, 1992

CLINICAL RESEARCH:

Sanofi-Aventis 1/2007-Present
–Sub Investigator
A Randomized, Open Label, Multicenter, Phase III,2-Arm Study of Androgen Withdrawal with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy.

Boston Scientific 5/2007-Present
–Sub Investigator
Post-Marketing Study using Prolieve(TM) for the Treatment of Benign Prostatic Hyperplasia (BPH).

Amgen, Inc. 3/2007-Present
–Sub Investigator

A Randomized, Double-Blind, Placebo-Controlled, Mutli-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer.

Solvay 3/2007- 5/2008
–Sub Investigator
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men.

Merck 7/2006-2007
–Sub Investigator
A Multi-center, double-blind, randomized, placebo-controlled, parallel-group, dose-ranging study of L-000796568 in postmenopausal women with overactive bladder.

Gtx, Inc. 1/2005-Present
–Sub Investigator
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men with High Grade Prostatic Intraepithelial Neoplasia (PIN).

Sanofi-Synthelabo, Inc. 10/2003-Present
–Investigator Initiated Protocol
An Open Label Study of Serum Testosterone Recovery and PSA after Six Months of Neo-Adjuvant Treatment with Eligard™ 22.5mg with Radiation Therapy in Patients with Early Stage Prostate Cancer.

GlaxoSmithKline, Inc. 6/2003-Present
–Sub Investigator
A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of dutasteride 0.5mg administered orally once daily for four years to reduce the risk of biopsy-detectable prostate cancer.

Schwarz Biosciences 7/2002-2007
–Sub Investigator
A Phase II, parallel group, stratified, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of mult-dosages of fesoteridine in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during the baseline urodynamic assessment.

Yamanouchi Pharma America 6/2004-11/2005
–Sub Investigator
Phase 3b
An Open Label Multicenter Study to Assess The Efficacy and Safety of Daily Oral Administration of 5 and 10 mg Vesicare (Solifenancin Succinate) in Patients Who Wish to Switch from Detrol LA? (Tolterdine Tartrate Extended Release) For The Treatment of Overactive Bladder Symtoms/YPA905-UC-006.

Dendreon Corporation 6/2004-9/2006
–Sub Investigator
A Randomized, Double-Blind, Placebo Controlled Phase 3 Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge (R), APC8015) in Asymptomatic Subjects with Gleason Sum 7 Metastatic, Androgen Independent Prostatic Adenocarcinomas.

ICOS Corporation 6/2003-9/2005
–Sub-Investigator
A Phase II, randomized, double-blind, placebo-controlled study of the safety and efficacy of RTX topical solution in patients with interstitial cystitis.

Eli Lilly 2000-8/2006
–Sub Investigator
Open Label. Long-term monitoring of safety in subjects treated with duloxetine for stress urinary incontinence.

Medtronics, Inc. 2001-2004
–Sub Investigator
Medtronics Interstim (R) Patient Registry.

Hoffman-La Roche, Inc. 5/2002-11/2004
–Sub Investigator
Randomized, double-blind, placebo-controlled, dose finding study to evaluate the effects of a partial alpha adrenoceptor agonist, Ro115-1240, in women with stress urinary incontinence or mixed urinary incontinence.

Hoffman-La Roche, Inc. 12/2002-1/2005
–Sub Investigator
NN16378 open-label extension for treatment of incontinent patients who have completed an Ro115-1240 study.

Merck, Inc. 6/2003- 7/2005
– Sub Investigator
A double-blind, randomized, placebo-controlled, multicenter study to evaluate the effects of rofecoxib in decreasing the risk of prostate cancer (ViP study).

GlaxoSmithKline, Inc. 6/2003-1/2005
–Sub Investigator
A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of dutasteride 0.5mg administered orally once daily for four years to reduce the risk of biopsy-detectable prostate cancer.

Novartis Pharmaceuticals 6/2003-10/2005
–Sub Investigator
A double-blind, placebo-controlled study of the effect of zolendronic acid on bone mineral density in men receiving androgen-deprivation therapy for prostate cancer.

Pfizer, Inc. 6/2003-1/2005
–Sub Investigator
A multicenter, randomized, parallel-group, double-blind, placebo-controlled, flexible dose escalation study to evaluate sexual and relationship satisfaction in the female partner of men with erectile dysfunction treated with Viagra (R) (sildenafil citrate) in the US.

GlaxoSmithKline, Inc. 6/2003-1/2005
–Sub Investigator
A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 10mg vardenafil.

GTx, Inc. 5/2002-5/2003
–Sub Investigator
A Phase II, four-arm, dose-finding, randomized, placebo-controlled study to determine the safety and efficacy of 20mg, 40mg and 60mg toremifene in the prevention of osteoporosis of androgen deprivation.

Pharmacia 5/2002-12/2002
–Sub Investigator

A double-blind, placebo-controlled, randomized US study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder (OAB).

Kyowa Pharmaceutical, Inc. 5/2002-12/2002
– Sub Investigator
A 6-week, double-blind, placebo-controlled randomized, parallel-group, multicenter, multidose study of the efficacy and safety of KW-7158 in patients with overactive bladder symptoms of increased urinary frequency, urgency and urge incontinence.

Health Decisions, Inc. 2001-7/2003
–Sub Investigator
A multicenter, pivotal Phase III, two-arm randomized placebo-controlled study to determine the chemoprevention efficacy and safety of 60mg daily of GTX-006 against high-grade prostate intraepithelial neoplasia (PIN).

Curon Corp, LLC 7/2001-5/2002
–Sub Investigator
Two-arm randomized, double-blind pilot herbal study for treatment of ureteral calculi.

Pharmacia & Upjohn 1999-2003
–Sub Investigator
A national Phase II trial of Interferon Alfa 2B (Intron A) plus BCG for treatment of superficial bladder cancer.

Reprogenesis, Inc. 1999-2001
–Sub Investigator
A randomized, controlled study comparing the safety and efficacy of Chondrogel-SI and Contigen for treatment of stress incontinence in women with intrinsic sphincter deficiency.

Pharmacia & Upjohn 1998-1999
–Sub Investigator
Long-term safety and efficacy of tolteradine prolonged release capsules.

American Medical System/Pfizer 1996-2003
– Sub Investigator
A multicenter prospective cohort study to evaluate the safety and effectiveness of the American Medical Systems' Ambicor inflatable penile prosthesis.

Medtronics, Inc. 1996-1998
– Sub Investigator
Randomized multicenter evaluation of the safety and effectiveness of the sacral nerve stimulation system for the treatment of urinary dysfunctional voiding patterns.

TAP Holdings, Inc. 1998-1999
–Sub Investigator
A Phase III safety and efficacy study of two fixed doses of apomorphine SL tablets versus placebo in the treatment of male erectile dysfunction in patients with controlled diabetes.

Eli Lilly and Company 1998-1999
–Sub Investigator
Duloxetine versus placebo in the relief of stress urinary incontinence.

Pharmacia & Upjohn 1998-1999
–Sub Investigator
Dose escalation study with tolteradine in patients with overactive bladder. A single-blind study in patients with symptoms of overactive bladder including urinary urgency and frequency with or without urge incontinence.

Reprogenesis, Inc. 1996-1999
–Sub Investigator
Protocol for the clinical investigation of an autologous tissue implant for the treatment of urinary incontinence.

Uromed Corporation 1993-1998
–Sub Investigator
Clinical investigation of a urethral occlusion device for the treatment of stress urinary incontinence.

Upjohn Company 1994-1996
–Sub Investigator
Phase III study of oral bropiramine versus intravesical BCG in adult patients with BCG-na?ve bladder carcinoma in-situ.

ABSTRACTS PRESENTED:

"Treatment of ISD Urinary Incontinence in Women Using Autologous Chondrocytes-Preliminary Results"
RF Tutrone Jr, A Bent, M McLennan, D Goldstein

Mid-Atlantic Section, AUA, Oct, 1999

"The use of oral Trazadone for the treatment of venogenic erectile dysfunction".
MJ Duckett, DS Goldstein, RB Goldstein, N Shackleford, LS Baker, RF Tutrone AUA 90th Annual Meeting, Las Vegas, NV, 1995.

"Inhibition of peritoneal tumor-cell implantation:
A model for laparoscopic cancer surgery".
DS Goldstein, ML Lu, T Hattori, TL Ratliff, KR Loughlin, LR Kavoussi.
AUA 88th Annual Meeting, San Antonio, TX, 1993.
10th World Congress on Endourology and ESWL, Singapore, 1992

"Laparoscopic cutaneous ureterostomy: A porcine model".
DS Goldstein, GT Ho,JA Scott, AL Lage, A Atala, KR Loughlin, LR Kavousst
Northeastern & New England Section AUA, Toronto, Canada, 1992.
10th World Congress on Endourology and ESWL, Singapore, 1992.
AUA 87th Annual Meeting, Washington, DC, 1992

"Laparoscopic correction of vesicoureteral reflux in an animal model".
A Atala, LR Kavoussi, DS Goldstein, AB Retik, CA Peters.
10th World Congress on Endourology and ESWL, Singapore, 1992.

"Laparoscopic radical nephrectomy".
LR Kavoussi, DS Goldstein, KR Loughlin.
Northeastern & New England Section, AUA, Toronto, Canada, 1992

"Intravesical therapy with BCG for transitional cell carcinoma of the bladder in a rat model".
RF Tutrone, DS Goldstein, MA ODonnell, G Brodsky, WC DeWolf, JP Richie
AUA 88th Annual Meeting, San Antonio, TX, 1993.
Northeastern & New England Section AUA, Toronto, Canada, 1992

"Prostate cancer screening: The role of digital rectal exam and prostate specific antigen".
JP Richie, LR Kavoussi, KR Laughlin, MA Vickers, MA ODonnell,
D St.Laurent, A Chen, DS Goldstein, GT Ho
Northeastern & New England Section AUA, Toronto, Canada, 1992

"Molecular characterization of a 67 kd laminin/elastin binding protein in human bladder carcinoma cell lines".
ML Lu, GT Ho, DS Goldstein, LB Chen, KR Loughlin, JP Richie
AUA 87th Annual Meeting, Washington, DC, 1992.

"Radioiodinated IUdR [*IUdR] Uptake in exfoliated cells obtained from patients with bladder cancer: Implications for diagnosis and therapy". AD Van den Abbeele, PD Barclay, RF Tutrone, DS Goldstein, GM Makrigiorgos, RM Berman, DS Weinberg, JP Richie, SJ Adelstein, Al Kassis Annual Radiation Research Society, Salt Lake City, Utah. March 14-18, 1992.

PROFESSIONAL AFFILIATIONS:

American Urological Association	1994-Present
Quality Assurance Committee GBMC Hospital	2006-Present
Cancer Committee, Union Hospital of Cecil County	2000-2008

Downtown Sailing Center
Member of the Board: 1995-Present

PUBLICATIONS:

RG Moore, DS Goldstein, LR Kavoussi: Laparoscopic Cutaneous Ureterostomy. In: Controversies in Endourology. Philadelphia, WB. Saunders Co., 1995

A Atala, LR Kavoussi, DS Goldstein, AB Retik, CA Peters: Laparoscopic correction of vesicoureteral reflux. J. Urol., 150 748-751, 1993.

DS Goldstein, ML Lu, T Hattori, TL Ratliff, KR Loughlin, LR Kavoussi.: "Inhibition of peritoneal tumor-cell implantation: A model for laparoscopic cancer surgery". J. Endourology, 7: 237-241, 1993

DS Goldstein, HN Winfield: Laparoscopic instrumentation. In. Laparoscopic Urologic Surgery. Edited by LG Gomella, M Kozminski, HN Winfield. New York. Raven Press, Ltd., Chapt. 4, pp. 21-52, 1993.

DS Goldstein, PS Chandhoke, LR Kavoussi: Laparoscopic equipment. In: Laparoscopic Urology. Edited by RV Clayman, EM McDougal. St. Louis: Quality Medical Publishing, Inc., Chapt. 8, pp 86-121, 1993.

DS Goldstein, PS Chandhoke, LR Kavoussi, RR Odem: Laparoscopic equipment. In: Essentials of Laparoscoy. Edited by NJ Soper, RR Odem, RV Clayman, EM McDougal. St. Louis: Quality Medical Publishing, Inc., pp 104-147, 1994

G Alpert, DS Goldstein Technique of endotracheal intubation in rats. Laboratory Animal Science, 32.78, 1980

NOTEWORTHY HONORS AND AWARDS:

First Prize

Endourological Society, Annual Essay Contest 1992

Editor In Chief
Mount Sinai School of Medicine Yearbook 1987